<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02649920</url>
  </required_header>
  <id_info>
    <org_study_id>CHD019-15</org_study_id>
    <nct_id>NCT02649920</nct_id>
  </id_info>
  <brief_title>Comparing the Efficiency of Cervical Ripening BALLoon (Cook) to the DINOprostone (Propess) for the Cervical Maturation in Case of Unfavorable Cervix (Bishop &lt;6) in the Population of Obese Pregnant Women (BMI &gt;= 30 kg/m²)</brief_title>
  <acronym>BALLODINO</acronym>
  <official_title>Pilot, Comparative, Not Randomized, Two Centers Study Comparing the Efficiency of Cervical Ripening BALLoon (Cook) to the DINOprostone (Propess) for the Cervical Maturation in Case of Unfavorable Cervix (Bishop &lt;6) in the Population of Obese Pregnant Women (BMI &gt;= 30 kg/m²)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Departemental Vendee</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Departemental Vendee</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      At the moment in France, one delivery on four is induced for a medical indication. In this&#xD;
      context, the practitioners are exposed to an additional difficulty when the clinical&#xD;
      examination of the patient reveals a unfavorable cervix because the main drug used for the&#xD;
      releases cannot be used and the cervix must be previously mature.&#xD;
&#xD;
      There is a pharmacological method used and estimated in these indications of cervical&#xD;
      maturation: the dinoprostone (Propess®).&#xD;
&#xD;
      Other methods using a mechanical process, are under development and of evaluation as it is&#xD;
      the case of the probe of dilation with double balloon (Cook®).&#xD;
&#xD;
      The population of the obese women is a population in constant increase in France and&#xD;
      presenting deliveries to higher risks of maternal and foetal complications. At these&#xD;
      patients, the medicinal releases seem also more difficult and at greater risks of failures.&#xD;
&#xD;
      The investigators wish compared the efficiency of the cervical ripening balloon to the&#xD;
      dinoprostone within the framework of a medical indication in a release with a unfavorable&#xD;
      cervix in obese pregnant women.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Actual">November 2016</completion_date>
  <primary_completion_date type="Actual">November 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bishop score after 24 hours of maturation</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Delivery</condition>
  <arm_group>
    <arm_group_label>Cervical ripening balloon</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prospective</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dinoprostone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Retrospective</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cervical ripening balloon</intervention_name>
    <arm_group_label>Cervical ripening balloon</arm_group_label>
    <other_name>Cook</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dinoprostone</intervention_name>
    <arm_group_label>Dinoprostone</arm_group_label>
    <other_name>Propess</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  Term ≥ 37 weeks of amenorrhea&#xD;
&#xD;
          -  Singleton pregnancy&#xD;
&#xD;
          -  Cephalic presentation&#xD;
&#xD;
          -  Medical indication of release and unfavorable cervix (Bishop &lt;6)&#xD;
&#xD;
          -  BM pre-pregnancy ≥ 30 kg/m2&#xD;
&#xD;
          -  Having given their agreement for the participation of the study&#xD;
&#xD;
          -  Patient receiving social coverage&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt; 18 years&#xD;
&#xD;
          -  Term &lt; 37 weeks of amenorrhea&#xD;
&#xD;
          -  Multiple pregnancy&#xD;
&#xD;
          -  Favorable cervix (Bishop ≥ 6)&#xD;
&#xD;
          -  Contraindication of vaginal delivery: praevia placenta, transverse presentation, cord&#xD;
             prolapse&#xD;
&#xD;
          -  Evolutive urinary tract infection (positive urine dip: leukocytes/ nitrites)&#xD;
&#xD;
          -  Not affiliated with a legal protection regime&#xD;
&#xD;
          -  Patient trust, guardianship, under legal protection measure, deprived of freedom&#xD;
&#xD;
        Balloon's contraindications:&#xD;
&#xD;
          -  Abnormal pelvis structure&#xD;
&#xD;
          -  Evolutive genital herpes&#xD;
&#xD;
          -  Invasive cervical cancer&#xD;
&#xD;
          -  Anomaly of foetal heart rate&#xD;
&#xD;
          -  Breech presentation&#xD;
&#xD;
          -  Maternal heart disorder&#xD;
&#xD;
          -  Hydramnios&#xD;
&#xD;
          -  Serious and uncontrolled arterial high blood pressure&#xD;
&#xD;
          -  Rupture of membranes&#xD;
&#xD;
          -  Medical histories of hysterotomy, classic uterine section, myomectomy or quite&#xD;
             different uterine section of full thickness&#xD;
&#xD;
          -  Presentation above superior pelvic strait&#xD;
&#xD;
        Dinoprostone's contraindications:&#xD;
&#xD;
          -  Scarred uterus&#xD;
&#xD;
          -  Prostaglandin's hypersensitivity&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guillaume DUCARME, PH</last_name>
    <role>Study Director</role>
    <affiliation>Centre Hospitalier Departemental Vendee</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Hospitalier Vendée</name>
      <address>
        <city>La Roche sur Yon</city>
        <zip>85925</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier</name>
      <address>
        <city>Le Mans</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <study_first_submitted>January 4, 2016</study_first_submitted>
  <study_first_submitted_qc>January 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 8, 2016</study_first_posted>
  <last_update_submitted>January 10, 2017</last_update_submitted>
  <last_update_submitted_qc>January 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>unfavorable cervix</keyword>
  <keyword>obese pregnant women</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dinoprostone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

